Curium US LLC

PARIS, July 21, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today the publication…
Read More...

<!-- Name:DistributionId Value:8788081 --> <!--…
Read More...

ST. LOUIS, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Curium, the world’s leading nuclear medicine company, announced today…
Read More...

Measures in place minimize impact of near-term molybdenum-99 shortageMore than ten years of Mo-99 supply chain…
Read More...

Submission follows the completion of Phase III PYTHON clinical trial of -DCFPyL for recurrent prostate cancer in Europe…
Read More...

ST. LOUIS, May 12, 2022 (GLOBE NEWSWIRE) -- Curium confirmed today no supply challenges of 177Lu-PSMA-I&T for the…
Read More...

ST. LOUIS, May 03, 2022 (GLOBE NEWSWIRE) -- Curium announced today it has successfully enrolled and dosed patients in…
Read More...

ST. LOUIS, April 19, 2022 (GLOBE NEWSWIRE) -- Curium announced today that it will be increasing production capacity…
Read More...

ST. LOUIS, April 05, 2022 (GLOBE NEWSWIRE) -- Curium announced today that its generic version of DaTscan (Ioflupane I…
Read More...